Leukemia surfaceome analysis reveals new disease-associated features

Blood

Volumn 121, Issue 25, 2013, Pages e149-e159

  Mirkowska, Paulina ^a,b,c   Hofmann, Andreas ^b,c   Sedek, Lukasz ^d   Slamova, Lucie ^e   Mejstrikova, Ester ^e   Szczepanski, Tomasz ^d   Schmitz, Maike ^a,c   Cario, Gunnar ^f   Stanulla, Martin ^f   Schrappe, Martin ^f   Van Der Velden, Vincent H J ^g   Bornhauser, Beat C ^a   Wollscheid, Bernd ^b   Bourquin, Jean Pierre ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b ETH ZURICH   (Switzerland)

^c Life Science Zurich   (Switzerland)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD157 ANTIGEN; CD18 ANTIGEN; CD19 ANTIGEN; CD217 ANTIGEN; CD305 ANTIGEN; CD31 ANTIGEN; CD317 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CD63 ANTIGEN; CD79B ANTIGEN; CD9 ANTIGEN; CD97 ANTIGEN; CELL SURFACE PROTEOME; CHEMOKINE RECEPTOR CXCR4; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; HERMES ANTIGEN; HLA DR ANTIGEN; ICAM2 PROTEIN; IL6ST PROTEIN; INTERCELLULAR ADHESION MOLECULE 2; ITGA6 PROTEIN; ITGB7 ANTIGEN; LYMPHOCYTE ANTIGEN; MESSENGER RNA; PROTEOME; SELL PROTEIN; TNFRSF1A PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; HEMATOPOIETIC CELL; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LEUKEMIA; LEUKEMIA CELL; MOUSE; NONHUMAN; PHENOTYPE; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEOMICS; ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL; DRUG SCREENING; IMMUNOLOGY; METABOLISM;

ANIMALS; ANTIGENS, CD; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MEMBRANE PROTEINS; MICE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEOME; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882290270     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-468702     Document Type: Article

References (49)

1. van Lochem EG, van der Velden VH, Wind HK, te Marvelde JG, Westerdaal NA, van Dongen JJ. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom. 2004;60(1):1-13.
2. Borowitz MJ, Bray R, Gascoyne R, et al. U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. Cytometry. 1997;30(5):236-244.
3. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. Cytometry B Clin Cytom. 2005;68(1):18-24.
4. van Dongen JJ, Lhermitte L, Böttcher S, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9): 1908-1975.
5. Borowitz MJ, Devidas M, Hunger SP, et al; Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood. 2008;111(12):5477-5485.
6. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol. 2009;27(31):5168-5174.
7. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008; 321(5891):974-977.
8. Meinhardt A, Burkhardt B, Zimmermann M, et al; Berlin-Frankfurt-Münster group. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28(19): 3115-3121.
9. Topp MS, Gökbuget N, Zugmaier G, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26):5185-5187.
10. Zwaan CM, Reinhardt D, Jürgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia. 2003; 17(2):468-470.
11. Bock T, Moest H, Omasits U, et al. Proteomic analysis reveals drug accessible cell surface N-glycoproteins of primary and established glioblastoma cell lines. J Proteome Res. 2012; 11(10):4885-4893.
12. Hofmann A, Gerrits B, Schmidt A, et al. Proteomic cell surface phenotyping of differentiating acute myeloid leukemia cells. Blood. 2010;116(13): e26-e34.
13. Wollscheid B, Bausch-Fluck D, Henderson C, et al. Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins. Nat Biotechnol. 2009;27(4): 378-386.
14. Lock RB, Liem N, Farnsworth ML, et al. The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood. 2002;99(11): 4100-4108.
15. Schmitz M, Breithaupt P, Scheidegger N, et al. Xenografts of highly resistant leukemia recapitulate the clonal composition of the leukemogenic compartment. Blood. 2011;118(7): 1854-1864.
16. Bonapace L, Bornhauser BC, Schmitz M, et al. Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistance. J Clin Invest. 2010;120(4):1310-1323.
17. Clappier E, Gerby B, Sigaux F, et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med. 2011;208(4): 653-661.
18. Schmitz M, Bourquin JP, Bornhauser BC. Alternative technique for intrafemoral injection and bone marrow sampling in mouse transplant models. Leuk Lymphoma. 2011;52(9):1806-1808.
19. Keller A, Eng J, Zhang N, Li XJ, Aebersold R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. Mol Syst Biol. 2005;1:2005.0017.
20. Bicocca VT, Chang BH, Masouleh BK, et al. Crosstalk between ROR1 and the Pre-B cell receptor promotes survival of t(1;19) acute lymphoblastic leukemia. Cancer Cell. 2012;22(5): 656-667.
21. Novershtern N, Subramanian A, Lawton LN, et al. Densely interconnected transcriptional circuits control cell states in human hematopoiesis. Cell. 2011;144(2):296-309.
22. Coustan-Smith E, Song G, Clark C, et al. New markers for minimal residual disease detection in acute lymphoblastic leukemia. Blood. 2011; 117(23):6267-6276.
23. Chen JS, Coustan-Smith E, Suzuki T, et al. Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia. Blood. 2001;97(7):2115-2120.
24. Rhein P, Mitlohner R, Basso G, et al. CD11b is a therapy resistance-and minimal residual diseasespecific marker in precursor B-cell acute lymphoblastic leukemia. Blood. 2010;115(18): 3763-3771.
25. Inukai T, Inaba T, Yoshihara T, Look AT. Cell transformation mediated by homodimeric E2A-HLF transcription factors. Mol Cell Biol. 1997;17(3):1417-1424.
26. Dworzak MN, Schumich A, Printz D, et al. CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112(10):3982-3988.
27. Kalina T, Flores-Montero J, van der Velden VH, et al; EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012; 26(9):1986-2010.
28. Granziero L, Circosta P, Scielzo C, et al. CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD51 B lymphocytes. Blood. 2003;101(5):1962-1969.
29. Trinidad EM, Ballesteros M, Zuloaga J, Zapata A, Alonso-Colmenar LM. An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood. 2009;114(24):5081-5090.
30. Lapalombella R, Yeh YY, Wang L, et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell. 2012;21(5):694-708.
31. Chao MP, Alizadeh AA, Tang C, et al. Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 2011; 71(4):1374-1384.
32. Zhang W, Trachootham D, Liu J, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012;14(3):276-286.
33. da Cunha JP, Galante PA, de Souza JE, et al. Bioinformatics construction of the human cell surfaceome. Proc Natl Acad Sci USA. 2009; 106(39):16752-16757.
34. Munoz J, Low TY, Kok YJ, et al. The quantitative proteomes of human-induced pluripotent stem cells and embryonic stem cells. Mol Syst Biol. 2011;7:550.
35. Lundberg E, Fagerberg L, Klevebring D, et al. Defining the transcriptome and proteome in three functionally different human cell lines. Mol Syst Biol. 2010;6:450.
36. Veltroni M, De Zen L, Sanzari MC, et al; I-BFMALL-FCM-MRD-Study Group. Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia. Haematologica. 2003;88(11): 1245-1252.
37. Dworzak MN, Gaipa G, Schumich A, et al. Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group. Cytometry B Clin Cytom. 2010;78(3): 147-153.
38. Gaipa G, Basso G, Maglia O, et al; I-BFMALL-FCM-MRD Study Group. Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection. Leukemia. 2005;19(1):49-56.
39. Dworzak MN, Fröschl G, Printz D, et al; Austrian Berlin-Frankfurt-Münster Study Group. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood. 2002;99(6): 1952-1958.
40. van Wering ER, van der Linden-Schrever BE, Szczepański T, et al. Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease. Br J Haematol. 2000;110(1):139-146.
41. Denys B, van der Sluijs-Gelling AJ, Homburg C, et al. Improved flow cytometric detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia. 2013;27(3): 635-641.
42. Conter V, Bartram CR, Valsecchi MG, et al. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study. Blood. 2010; 115(16):3206-3214.
43. Bader P, Kreyenberg H, Henze GH, et al; ALL-REZ BFM Study Group. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group. J Clin Oncol. 2009; 27(3):377-384.
44. Nyvold C, Madsen HO, Ryder LP, et al; Nordic Society for Pediatric Hematology and Oncology. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood. 2002;99(4):1253-1258.
45. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009;10(2):147-156.
46. Hüttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012;4(142):142ra94.
47. Gillet LC, Navarro P, Tate S, et al. Targeted data extraction of the MS/MS spectra generated by data-independent acquisition: a new concept for consistent and accurate proteome analysis. Mol Cell Proteomics. 2012;11(6):O111.016717.
48. Bendall SC, Simonds EF, Qiu P, et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science. 2011;332(6030):687-696.
49. Bodenmiller B, Zunder ER, Finck R, et al. Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators. Nat Biotechnol. 2012;30(9):858-867.